论文部分内容阅读
目的:探讨西格列汀联合金匮肾气丸对2型糖尿病伴心脑血管病变患者血清Hcy、纤维蛋白原及细胞炎症因子水平的影响。方法:选取本院诊断并治疗的2型糖尿病伴心脑血管病患者96例,按随机数字表法分组,对照组48例予以常规治疗,研究组48例予以西格列汀联合金匮肾气丸治疗,检测并记录血糖状况、炎症因子及血清Hcy、纤维蛋白原、血液流变学状况,同时对比临床疗效及不良反应状况。结果:对照组临床有效率77.08%与研究组临床有效率91.67%数据对比,有显著性差异(P<0.05);相对于治疗前,两组治疗后FBG、2 h PBG、FINS及Hb Alc含量降低,治疗后炎症因子及血清Hcy、纤维蛋白原含量均降低,治疗后全血黏度、血浆黏度及ESR均降低,有显著性差异(P<0.05);相对于对照组,研究组治疗后FBG、2 h PBG、FINS及Hb Alc含量较低,治疗后炎症因子及血清Hcy、纤维蛋白原含量较低,治疗后全血黏度、血浆黏度及ESR较低,有显著性差异(P<0.05)。结论:西格列汀联合金匮肾气丸能降低2型糖尿病伴心脑血管病变患者血清Hcy、纤维蛋白原及细胞免疫因子水平,效果显著。
Objective: To investigate the effects of sitagliptin combined with Jingui Shenqi Pill on serum Hcy, fibrinogen and inflammatory cytokines in type 2 diabetic patients with cardiovascular and cerebrovascular diseases. Methods: Ninety-six patients with type 2 diabetes mellitus and cardio-cerebrovascular disease diagnosed and treated in our hospital were selected and randomly divided into groups according to random number table. 48 patients in the control group were treated routinely. 48 patients in the study group were treated with sitagliptin and Jingu Shen Pill treatment, detection and record of blood glucose status, inflammatory cytokines and serum Hcy, fibrinogen, hemorheology, while comparing the clinical efficacy and adverse reactions. Results: Compared with the clinical effective rate of 91.67%, the clinical effective rate of the control group was significantly higher than that of the control group (77.08%, P <0.05). Compared with the two groups before treatment, FBG, 2 h PBG, FINS and Hb Alc After treatment, the levels of inflammatory cytokines, serum Hcy and fibrinogen decreased, while the whole blood viscosity, plasma viscosity and ESR decreased after treatment (P <0.05). Compared with the control group, the FBG , Lower content of PBG, FINS and Hb Alc after 2 h, lower inflammatory cytokines, serum Hcy and fibrinogen after treatment, lower whole blood viscosity, lower plasma viscosity and ESR after treatment (P <0.05) . Conclusion: Sitagliptin combined with Jinkuishenqi Pill can reduce serum Hcy, fibrinogen and cellular immune factors in type 2 diabetic patients with cardiovascular and cerebrovascular diseases, the effect is significant.